Salarius Pharmaceuticals, Inc. Quarterly Operating Income (Loss) in USD from Q3 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Salarius Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2015 to Q3 2024.
  • Salarius Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$1.01M, a 60.3% increase year-over-year.
  • Salarius Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$5.22M, a 71.7% increase year-over-year.
  • Salarius Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$12.9M, a 59.5% increase from 2022.
  • Salarius Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$31.8M, a 149% decline from 2021.
  • Salarius Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$12.8M, a 64.6% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$5.22M -$1.01M +$1.53M +60.3% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$6.74M -$1.47M +$2.5M +63% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$9.25M -$1.77M +$3.65M +67.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$12.9M -$971K +$5.51M +85% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-22
Q3 2023 -$18.4M -$2.53M +$12M +82.5% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$30.4M -$3.97M +$787K +16.5% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$31.1M -$5.42M +$697K +11.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$31.8M -$6.48M -$2.33M -56.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-22
Q3 2022 -$29.5M -$14.5M -$10.7M -287% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$18.8M -$4.76M -$1.64M -52.7% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$17.1M -$6.12M -$4.31M -239% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-11
Q4 2021 -$12.8M -$4.14M -$2.39M -136% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-27
Q3 2021 -$10.4M -$3.75M -$1.99M -113% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$8.44M -$3.12M -$1.22M -64% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-05
Q1 2021 -$7.22M -$1.8M +$565K +23.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 -$7.79M -$1.76M +$303K +14.7% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-25
Q3 2020 -$8.09M -$1.76M +$2M +53.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$10.1M -$1.9M -$989K -108% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$9.1M -$2.37M -$837K -54.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 -$8.27M -$2.06M -$38.9K -1.92% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-18
Q3 2019 -$8.23M -$3.76M -$3.45M -1099% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$4.78M -$912K +$8.19M +90% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 -$13M -$1.53M +$6.75M +81.5% Jan 1, 2019 Mar 31, 2019 10-Q/A 2020-05-15
Q4 2018 -$19.7M -$2.02M +$6.07M +75% Oct 1, 2018 Dec 31, 2018 10-K 2019-03-06
Q3 2018 -$25.8M -$314K +$9.1M +96.7% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$34.9M -$9.1M -$227K -2.55% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-17
Q1 2018 -$34.7M -$8.28M +$63.4K +0.76% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-01
Q4 2017 -$34.7M -$8.09M -$109K -1.36% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-06
Q3 2017 -$34.6M -$9.41M +$1.33M +12.4% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-06
Q2 2017 -$35.9M -$8.88M +$2.59M +22.6% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-06
Q1 2017 -$38.5M -$8.35M +$1.35M +13.9% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-06
Q4 2016 -$39.9M -$7.98M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-07
Q3 2016 -$10.7M -$2.57M -31.4% Jul 1, 2016 Sep 30, 2016 10-K 2018-03-07
Q2 2016 -$11.5M Apr 1, 2016 Jun 30, 2016 10-K 2018-03-07
Q1 2016 -$9.7M Jan 1, 2016 Mar 31, 2016 10-K 2018-03-07
Q3 2015 -$8.17M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.